Australian Business Review

Richard Pestell was six when he first faced the devastating consequences of cancer.  His best friend died from the disease and then he watched both his parents die from it, so it’s no surprise he has devoted his medical career to that field.

“It’s not about getting mad but getting even,” he said.
Read More

Categories: News

Tags:

News Coverage: Aussies at SpaceX, Apple, Google, Planet Labs and Emotiv lead the talent diaspora

Australia has a talented diaspora of one million Australians overseas. A country of 24 million cannot afford to lose touch with its citizens thriving in the talent hotspots of the world. They might live overseas, but they are still part of the national conversation and economy – they are a network and an ambassadorial corps for Australia, its knowledge economy and research capacity. They are a soft-power asset. They might be out of sight, but they should not be out of mind.

Dr Richard Pestell, Director, Sidney Kimmel, Cancer Center, Thomas, Jefferson University: Dr Richard Pestell unites academic excellence and scientific discovery. His work has galvanised international teams to fight cancer with his cancer-diagnosis and treatment innovations. Pestell founded prostate cancer diagnostic and therapeutic company ProstaGene and light-activated gene therapy company AAAPhoenix. ProstaGene is currently testing a new treatment for metastatic prostate cancer that has proved effective blocking bone, brain and lung metastasis in preclinical testing. He has led cancer not–for-profits and directed two US cancer centres.

Read the full article @ The Australian Business Review

Categories: News

World – renowned physician Dr. Richard G. Pestell joins the Baruch S. Blumberg Institute

Specialist takes lab, startup to bio center

DOYLESTOWN, Pa.–(BUSINESS WIRE)–World-renowned cancer physician scientist Richard G. Pestell, M.D., Ph.D., has joined the Baruch S. Blumberg Institute to establish and serve as president of the Pennsylvania Cancer and Regenerative Medicine Research Center (PCARM). Seven additional faculty with their staff and students also will be joining the new center.

Pestell’s research in cell cycle, prostate cancer, oncology and stem cells is highly cited; he is ranked first in the world by Google scholar citations in cell cycle and prostate cancer, and second in the world for oncology. Pestell is funded by more than $1 million each year in grant support from the National Cancer Institute (NCI) of the National Institutes of Health (NIH), the Breast Cancer Research Foundation, and the Falk Foundation.

“Dr. Pestell’s recruitment will go a long way toward helping us achieve our goal of finding a cure for diseases associated with hepatitis B,” said Timothy Block, Ph.D., president of the Hepatitis B Foundation and its Baruch S. Blumberg Institute, and the Pennsylvania Biotechnology Center, where both are headquartered. “His research complements the work conducted at the Blumberg Institute, which was established in 2003 by the Hepatitis B Foundation to find a cure for hepatitis B and liver cancer.”

Pestell previously was Director of the Sidney Kimmel Cancer Center and Executive Vice President at Thomas Jefferson University in Philadelphia. Under his tenure, the Sidney Kimmel Cancer Center received renewed National Cancer Institute funding and designation.

In addition to leading PCARM at the Blumberg Institute, Pestell will oversee ProstaGene, one of the biotechnology companies he founded. ProstaGene has patented discoveries for cancer metastasis therapies and a highly predictive genetic test for prostate cancer outcome. The company is being moved to the Pennsylvania Biotechnology Center, a biotech incubator managed and owned by the Blumberg Institute and Hepatitis B Foundation; 35 other start-up life science companies also are housed at the center.

“The interface between cancer, stem cells, and regeneration is at an historic moment. Creating a culture in which biotechnology companies are a vehicle to unlock value is key to bringing benefits rapidly to our patients,” said Pestell. “The Blumberg Institute, under its president, Dr. Timothy Block, has a remarkable track record of success in developing companies that rapidly translate urgently needed medical discoveries into clinical practice.”

Pestell has published more than 600 works and is the most frequently cited scientist in his fields of cell-cycle and prostate cancer. He serves as an advisor and reviewer for a number of domestic and international research centers, including NCI cancer centers. He is the recipient of numerous national and international awards and recognitions, including election as Fellow, American Association for the Advancement of Science.

The arrival of Pestell and his research team comes at an opportune time, as the Pennsylvania Biotechnology Center, located in Bucks County, proceeds with plans to break ground for a $10.6 million expansion. The project will add 50,000 square feet of additional space, including at least 40 offices, 18 laboratories, a new auditorium, a new cafeteria and 100 parking spaces.

About the Baruch S. Blumberg Institute: The Baruch S. Blumberg Institute is an independent, nonprofit research institute established in 2003 by the Hepatitis B Foundation to conduct discovery research and nurture translational biotechnology in an environment conducive to interaction, collaboration and focus. It was renamed in 2013 to honor Baruch S. Blumberg, who won the Nobel Prize for his discovery of the hepatitis B virus and co-founded the Hepatitis B Foundation. To learn more, visit www.blumberginstitute.org.

See the full article at Businesswire

Categories: News

Philadelphia Business Journal Article: Main Line biotech firm advancing technology to help diagnose, treat prostate cancer

Quote

New Article on ProstaGene in the Philadelphia Business Journal from Senior Reporter John George:

A Montgomery County biotechnology company has raised $400,000 from private investors.

ProstaGene, which is based at the Lankenau Institute for Medical Research in Wynnewood, Pa., has developed a gene-based technology to help guide treatment decisions for patients with a type of cancer where immediate treatment is not always recommended.

ProstaGene is developing gene-based technology to diagnose and treat prostate cancer.
Read More

Categories: News

Tags: